Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.33.

ZURA has been the topic of several analyst reports. Oppenheimer cut their target price on Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, May 9th. Guggenheim reissued a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating on shares of Zura Bio in a research note on Thursday, April 3rd.

Zura Bio Stock Down 1.9%

Zura Bio stock opened at $1.02 on Friday. The business’s 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.82. The stock has a market cap of $69.74 million, a price-to-earnings ratio of -1.46 and a beta of 0.05. Zura Bio has a 12-month low of $0.97 and a 12-month high of $5.56.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). As a group, sell-side analysts expect that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

A number of hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the first quarter worth about $72,000. Allostery Investments LP raised its position in shares of Zura Bio by 44.2% during the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock worth $3,005,000 after purchasing an additional 714,258 shares during the period. ADAR1 Capital Management LLC raised its position in shares of Zura Bio by 34.9% during the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock worth $3,614,000 after purchasing an additional 723,933 shares during the period. Armistice Capital LLC raised its position in shares of Zura Bio by 2.4% during the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $1,981,000 after purchasing an additional 36,000 shares during the period. Finally, Forefront Analytics LLC raised its position in shares of Zura Bio by 101.6% during the first quarter. Forefront Analytics LLC now owns 108,308 shares of the company’s stock worth $140,000 after purchasing an additional 54,574 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.